SynchNeuro is a Portfolio Company of Boomerang Ventures INDIANAPOLIS, IN / ACCESS Newswire / November 12, 2025 / Boomerang Ventures adds SynchNeuro, Inc. to its portfolio of seed-stage investments, ...
PreEvnt aims for Isaac to help people with type 1, type 2 and pre-diabetes, reducing the need for or frequency of ...
A distinct type of immune cells was found in pancreas of type 1 diabetic people; the discovery offers target for early ...
There were rumblings that the Apple Watch could get a redesign as soon as next year, but a new rumor suggests we might be ...
Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. Although it can present with an ...
Smartwatch trends in 2025 bring larger screens, advanced sensors, and AI-driven health tracking, making wearable tech updates ...
Researchers from IIT Madras have developed an affordable and minimally invasive glucose monitoring device. The device offers ...
BELLEVUE, Wash., Nov. 6, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the key findings from a company-sponsored pilot study conducted by Woori IO, an OSR Company, in ...
Diabetes can be dangerous. It can slowly damage the eyes long before symptoms appear. Experts stress that annual eye exams, ...
Neck circumference is closely related to cardiovascular disease CVD and other CVD risk factors Heres what doctor says ...
This collaboration supports the advancement of the EpiCapture test, which is currently in late-stage development, to regulatory approval and commercialization. This initiative is part of Trinity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback